Musa, Mary Jane .
HRN: 27-86-73 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/23/2025
CO-AMOXICLAV 625MG (TAB)
11/23/2025
11/30/2025
ORAL
625mg
BID
S/P NSD With Repair
Checking Initial Appropriateness
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines